Zimmer Biomet Holdings, Inc. Investigated by the Portnoy Law Firm
Get Alerts ZBH Hot Sheet
Join SI Premium – FREE
LOS ANGELES, March 06, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Zimmer Biomet Holdings, Inc., (“Zimmer" or the "Company") (NYSE: ZBH) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/zimmer-biomet-holdings-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
Zimmer’s stock price fell $15.63, or 15.2%, to close at $87.55 per share on November 5, 2025, thereby injuring investors. This occurred following the news on November 5, 2025, that Zimmer released its third quarter 2025 financial results, reporting net sales of approximately $2 billion. The Company attributed these results to “weakness in Latin America, Emerging Markets in Europe and non-core businesses” and lowered the top end of its full-year organic revenue growth forecast from 4.5% to 4.0%. This reduction was due, in part, to “the modest slowdown in the U.S. revision market for both hips and knees persisting throughout the rest of 2025” as well as “continued weakness in restorative therapies.”
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
Source: Portnoy Law
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
- Moody’s upgrades Cushman & Wakefield rating to Ba3 on debt reduction
- RegenLab targets Nasdaq listing under ticker RGNA as revenues top $29 million
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share